Takahiro Uotani
Hamamatsu University School of Medicine
5 Papers
Takahiro Uotani is an academic researcher from Hamamatsu University School of Medicine. The author has contributed to research in topics: Esomeprazole & Vonoprazan. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
Takuma Kagami,Shu Sahara,Hitomi Ichikawa,Takahiro Uotani,Mihoko Yamade,Mitsushige Sugimoto,Yasushi Hamaya,Moriya Iwaizumi,Satoshi Osawa,Ken Sugimoto,Hiroaki Miyajima,Takahisa Furuta +11 more
TL;DR: Acid inhibitory effects of proton pump inhibitors (PPIs) are influenced by CYP2C19 genotype, while the potent acid inhibition of vonoprazan is not influenced by cyp2C20 genotype.
217
High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication
Takahisa Furuta,Satoshi Baba,Mihoko Yamade,Takahiro Uotani,Takuma Kagami,Takahiro Suzuki,Shinya Tani,Yasushi Hamaya,Moriya Iwaizumi,Satoshi Osawa,Ken Sugimoto +10 more
TL;DR: Although autoimmune gastritis is generally considered relatively rare, it frequently encounter AIG among patients at to the authors' hospital who have experienced at least two episodes of Helicobacter pylori eradication failure.
45
High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy.
Takuma Kagami,Mihoko Yamade,Takahiro Suzuki,Takahiro Uotani,Shinya Tani,Yasushi Hamaya,Moriya Iwaizumi,Satoshi Osawa,Ken Sugimoto,Satoshi Baba,Haruhiko Sugimura,Hiroaki Miyajima,Takahisa Furuta +12 more
TL;DR: Targeting CD44v8-10-xCT-GSH axis inhibition may improve the prognosis of post-dCRT E-SCC patients and was an independent prognostic factor in E- SCC patients treated with dCRT.
One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19
Takuma Kagami,Mitsushige Sugimoto,Hitomi Ichikawa,Shu Sahara,Takahiro Uotani,Mihoko Yamade,Yasushi Hamaya,Moriya Iwaizumi,Satoshi Osawa,Ken Sugimoto,Hiroaki Miyajima,Takahisa Furuta +11 more
TL;DR: The one-day front-loading regimen of rabeprazole 10 mg qid provided sufficient acid inhibition for 7 days, even in CYP2C19 EMs.
Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype
Takuma Kagami,Mihoko Yamade,Takahiro Suzuki,Takahiro Uotani,Yasushi Hamaya,Moriya Iwaizumi,Satoshi Osawa,Ken Sugimoto,Kazuo Umemura,Hiroaki Miyajima,Takahisa Furuta +10 more
TL;DR: Vonoprazan attenuated the antiplatelet function of clopidogrel more potently than esomeprazole and did not affect that of prasugrel irrespective of CYP2C19 genotype.